Is Krystal Biotech Inc (KRYS) overvalued? · P/E 46, rev $290.5M
Krystal Biotech Inc (KRYS) is a biotechnology company listed on NASDAQ.
This page asks whether Krystal Biotech Inc (KRYS) looks expensive on cached numbers — not a short thesis.
Latest reported KRYS revenue for 2024-12-31 was $290.5M. Net income was $89.2M. Revenue was up 473.0% from 2023-12-31 to 2024-12-31. KRYS currently screens at market cap $10.17B and trailing P/E 46.1.
KRYS currently screens at market cap $10.17B and trailing P/E 46.1. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next KRYS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the KRYS stock page for the full model, not this heading.
Not investment advice.